<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104582</url>
  </required_header>
  <id_info>
    <org_study_id>Biliary drainage in KT</org_study_id>
    <nct_id>NCT03104582</nct_id>
  </id_info>
  <brief_title>Best Biliary Drainage Option in Advanced Klatskin Tumor</brief_title>
  <official_title>Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor：ERCP or PTBD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the biliary drainage-related cholangitis and other complications of
      percutaneous transhepatic biliary drainage (PTBD) in the management of Klatskin tumor (KT)
      compared with endoscopic biliary drainage (EBD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Operative treatment combined with preoperative biliary drainage (PBD) has been established
      as a safe management strategy for KT. Preoperative cholangitis was an independent risk
      factor for patients undergoing resection for KT. However, controversy exists regarding the
      preferred technique for PBD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2011</start_date>
  <completion_date type="Anticipated">July 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute cholangitis</measure>
    <time_frame>2 weeks</time_frame>
    <description>Acute cholangitis is defined if patients experienced abdominal pain, high fever, or chill after procedure in 2 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain</measure>
    <time_frame>2 weeks</time_frame>
    <description>Pain score (scores:1-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>6 months</time_frame>
    <description>The total time of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall procedure related complication rate</measure>
    <time_frame>6 months</time_frame>
    <description>Pancreatitis, bleeding, perforation, seeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cholangitis</condition>
  <arm_group>
    <arm_group_label>Biliary drainage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary drainage 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP Drainage</intervention_name>
    <description>When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.</description>
    <arm_group_label>Biliary drainage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTBD Drainage</intervention_name>
    <description>When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.</description>
    <arm_group_label>Biliary drainage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type II、III、IV Klatskin tumor patients;

          -  18-90 years old

        Exclusion Criteria:

          -  Unwillingness or inability to consent for the study;

          -  Coagulation dysfunction (INR&gt; 1.3) and low peripheral blood platelet count(&lt;50×109 /
             L) or using anti-coagulation drugs;

          -  Previous endoscopic sphincterectomy (EST) or endoscopic papillary balloon dilatation
             (EPBD);

          -  Any type of GI reconstruction;

          -  Combined with Mirizzi syndrome and intrahepatic bile duct stones;

          -  Preoperative coexistent diseases: acute pancreatitis, GI tract hemorrhage, severe
             liver disease, primary sclerosing cholangitis (PSC), septic shock;

          -  Biliary-duodenal fistula;

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xun Li, M.D., Ph. D.</last_name>
    <role>Study Director</role>
    <affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongjiang Ba, M.D</last_name>
    <phone>+8618893110409</phone>
    <email>bayj15@lzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenbo Meng, M.D., Ph. D.</last_name>
    <phone>+8613919177177</phone>
    <email>mengwb@lzu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatopancreatobiliary Surgery Institute of Gansu Province</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xun Li, M. D.</last_name>
      <phone>+8613993138612</phone>
      <email>drlixun@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>March 25, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Wenbo Meng</investigator_full_name>
    <investigator_title>M.D., Ph. D,</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>PTBD</keyword>
  <keyword>EBD</keyword>
  <keyword>Cholangitis</keyword>
  <keyword>Complication</keyword>
  <keyword>Klatskin tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
